Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) will release its financial results for Q2 2021 after market close on August 4, 2021. A conference call with management will follow at 1:30 PM PT/4:30 PM ET, accessible via their website. The company focuses on decoding the adaptive immune system to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. They boast three commercial products and a comprehensive clinical pipeline aimed at personalized immune-driven therapies.

Positive

• Adaptive Biotechnologies has three commercial products.
• Robust clinical pipeline targeting cancer, autoimmune conditions, and infectious diseases.

Negative

• None.

SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4, 2021. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its Q2 2021 financial results?

Adaptive Biotechnologies will report its Q2 2021 financial results on August 4, 2021.

What time is the Adaptive Biotechnologies conference call for Q2 2021?

The conference call will begin at 1:30 PM Pacific Time on August 4, 2021.

Where can I listen to the Adaptive Biotechnologies conference call?

The conference call can be accessed via the 'Investors' section of the Adaptive Biotechnologies website.

What are the main focuses of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on leveraging the adaptive immune system for diagnostics and therapies.